OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Advances is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	248
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	146
Addressing and overcoming disparities in GVHD	137
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	133
On a collision course: SARS-CoV-2 variants and CAR T cells	127
Cortisol in sickle cell disease: a systematic review and meta-analysis	121
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis	120
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	115
Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease	113
Transfusion therapy for sickle cell disease: what’s new?	108
Best but not perfect: indirect measure of low iron stores	103
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	95
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv.	94
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood	93
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv.	93
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	90
Steroid tapering after GVHD Rx: not too fast, not too slow	88
Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria	86
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	86
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	83
Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation	82
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	82
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	80
Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma	79
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction	77

Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel	76
Regional brain age is decreased in children with sickle cell anemia	74
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	72
Complement C5 inhibition in early onset HELLP syndrome	71
Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019	70
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	69
Persistence of PET scan positivity after chemoimmunotherapy for DLBCL	68
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis	67
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	67
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	66
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	65
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	65
HMA + venetoclax triplet regimens for the initial treatment of AML in adults- CONTRA	64
Cystic fibrosis and sickle cell disease associated with nonadministration of VTE prophylaxis in hospitalized adults	62
A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies	62
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	62
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	61
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	61
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial	61
Myelodysplastic Syndromes in VEXAS	60
Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel	60
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	59
CD58 loss in tumor cells confers functional impairment of CAR T cells	59
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma	58
Targeting bone marrow mesenchymal stromal cell–derived IL-6 to overcome acute myeloid leukemia chemoresistance	58
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model	58
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	58
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	57
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	57
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	57
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	56
Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma	56